Details of the Drug Combinations

General Information of This Drug (ID: DM8I94Y)

Drug Name
Venetoclax   DM8I94Y
Synonyms Venclexta
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

69 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Dexamethasone + Venetoclax DCM59BB Dexamethasone Relapsed/Refractory Multiple Myeloma [2]
Dexamethasone + Venetoclax DC0T6J6 Dexamethasone Relapsed/Refractory Multiple Myeloma [3]
Duvelisib + Venetoclax DCA4EJ0 Duvelisib Chronic Lymphocytic Leukemia [4]
Lenalidomide + Venetoclax DC4DEDR Lenalidomide Recurrent B-Cell Non-Hodgkin Lymphoma [5]
Lenalidomide + Venetoclax DCDZZ75 Lenalidomide B-Cell Lymphoma, Unspecified [6]
Rifampicin + Venetoclax DC4WBX2 Rifampicin Non-Hodgkin's Lymphoma [7]
Ruxolitinib + Venetoclax DCKV4R4 Ruxolitinib Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome [8]
Selinexor + Venetoclax DCDJGS3 Selinexor Diffuse Large B-cell Lymphoma [9]
Venetoclax + AC220 DC4UD35 AC220 Leukemia, Myeloid, Acute [10]
Venetoclax + ABT-263 DCCG0Q9 ABT-263 Myeloid Malignancy [11]
Venetoclax + Ivosidenib DCGGTZ7 Ivosidenib Acute Myeloid Leukemia [12]
Venetoclax + Decitabine DCHCDTI Decitabine Acute Myelogenous Leukemia [13]
Venetoclax + Daunorubicin DCHOPE8 Daunorubicin Acute Myeloid Leukemia [14]
Venetoclax + Azacitidine DCLNFXB Azacitidine Recurrent Acute Myeloid Leukemia [15]
Venetoclax + Azacitidine DCMRE6O Azacitidine Acute Myeloid Leukemia (AML) [16]
Venetoclax + AC220 DCNERRM AC220 Leukemia, Myeloid, Acute [10]
Venetoclax + APR-246 DCVHB79 APR-246 Myeloid Malignancy [17]
Venetoclax + Ketoconazole DC0FE2V Ketoconazole Non-Hodgkin's Lymphoma [18]
Venetoclax + Azacitidine DC0TMY5 Azacitidine Myelodysplastic Syndromes (MDS) [19]
Venetoclax + Cotellic DC1T534 Cotellic Leukemia, Myeloid, Acute [20]
Venetoclax + Omacetaxine mepesuccinate DC23R8P Omacetaxine mepesuccinate Hematopoietic and Lymphoid Cell Neoplasm [21]
Venetoclax + RG7388 DC41BE9 RG7388 Leukemia, Myeloid, Acute [20]
Venetoclax + Spironolactone DC5CFAI Spironolactone Acute Myeloid Leukemia [22]
Venetoclax + Pitavastatin DC63ETM Pitavastatin Acute Myeloid Leukemia [23]
Venetoclax + Cytarabine DC72TT8 Cytarabine Acute Myelogenous Leukemia [24]
Venetoclax + Mercaptopurine DC7PHD5 Mercaptopurine Acute Myeloid Leukemia, in Relapse [25]
Venetoclax + Umbralisib DC9U6PJ Umbralisib Chronic Lymphocytic Leukemia [26]
Venetoclax + Irinotecan DCAHIWV Irinotecan Relapsed Small Cell Lung Cancer [27]
Venetoclax + 8-chloro-adenosine DCE32LR 8-chloro-adenosine Acute Myeloid Leukemia [28]
Venetoclax + Enasidenib DCEET48 Enasidenib Acute Myeloid Leukemia [29]
Venetoclax + Decitabine DCEFOXE Decitabine Acute Myelogenous Leukemia [13]
Venetoclax + Flavopiridol DCF4LAK Flavopiridol Acute Myeloid Leukemia (AML) [30]
Venetoclax + Trabectedin DCFWL4S Trabectedin Refractory Chronic Lymphocytic Leukemia [31]
Venetoclax + Omacetaxine mepesuccinate DCGGYCF Omacetaxine mepesuccinate Relapsed or Refractory Hematologic Malignancies [32]
Venetoclax + Bay 80-6946 DCGR5B8 Bay 80-6946 Non-Hodgkin Lymphoma [33]
Venetoclax + Gilteritinib DCGVZVC Gilteritinib Acute Myeloid Leukemia (AML) [34]
Venetoclax + Capecitabine DCH24X1 Capecitabine Breast Cancer [35]
Venetoclax + ABT-263 DCJPVLH ABT-263 Acute Lymphoblastic Leukemia [36]
Venetoclax + Tazemetostat DCL9LMM Tazemetostat Lymphoma, Non-Hodgkin [37]
Venetoclax + Azacitidine DCM504K Azacitidine Acute Myelogenous Leukemia [13]
Venetoclax + Decitabine DCQ6GM6 Decitabine Acute Myeloid Leukemia [38]
Venetoclax + Enzalutamide DCS9N1Z Enzalutamide Castration Levels of Testosterone [39]
Venetoclax + AC220 DCSKJGQ AC220 Acute Myeloid Leukemia With FLT3/ITD Mutation [40]
Venetoclax + Bay 80-6946 DCTO2Z4 Bay 80-6946 Diffuse Large B Cell Lymphoma [41]
Venetoclax + SCH 727965 DCTTU24 SCH 727965 Cancer - Acute Myeloid Leukemia [42]
Cladribine + Venetoclax DC5SGO6 Cladribine Acute Myeloid Leukemia [43]
Cladribine + Venetoclax DCSF8IM Cladribine Acute Myeloid Leukemia [43]
Cobicistat + Venetoclax DC3CL07 Cobicistat AML, Adult [44]
Dexamethasone + Venetoclax DC5U64N Dexamethasone Multiple Myeloma [45]
Flumatinib + Venetoclax DCY4KNM Flumatinib Philadelphia Chromosome [46]
Fulvestrant + Venetoclax DCESOVP Fulvestrant Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer [47]
Selinexor + Venetoclax DCD4CLW Selinexor AML [48]
Selinexor + Venetoclax DCV3MVY Selinexor AML, Adult [49]
Tamibarotene + Venetoclax DC0T79H Tamibarotene Acute Myeloid Leukemia [50]
Trametinib + Venetoclax DCOYZ54 Trametinib Recurrent Acute Myeloid Leukemia [51]
Venetoclax + Enasidenib DC7JN75 Enasidenib Acute Myeloid Leukemia [52]
Venetoclax + Venetoclax DCRHK4P Venetoclax Mantle Cell Lymphoma [53]
Venetoclax + Omacetaxine mepesuccinate DCIR4BI Omacetaxine mepesuccinate Acute Myeloid Leukemia [54]
Venetoclax + Ibrutinib DC36D1X Ibrutinib Mantle Cell Lymphoma [55]
Venetoclax + Bortezomib DC48LQA Bortezomib High Grade B-Cell Lymphoma, Not Otherwise Specified [56]
Venetoclax + Zanubrutinib DC6ULV1 Zanubrutinib Chronic Lymphocytic Leukemia (CLL) [57]
Venetoclax + Romidepsin DCE49GC Romidepsin Anaplastic Large Cell Lymphoma [58]
Venetoclax + APR-246 DCGU65J APR-246 Recurrent Mantle Cell Lymphoma [59]
Acalabrutinib + Venetoclax DC04QN3 Acalabrutinib Chronic Lymphocytic Leukemia [60]
Acalabrutinib + Venetoclax DCMHUZ1 Acalabrutinib Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [61]
Dexamethasone + Venetoclax DC2V68Y Dexamethasone Relapsed/Refractory Multiple Myeloma [62]
Venetoclax + Decitabine DCYAMOZ Decitabine Acute Myeloid Leukemia [63]
Venetoclax + Ibrutinib DCOMIIC Ibrutinib Leukemia, Lymphocytic, Chronic, B-Cell [64]
Venetoclax + Ibrutinib DCBV2M1 Ibrutinib Chronic Lymphocytic Leukemia [65]
------------------------------------------------------------------------------------
⏷ Show the Full List of 69 DrugCom(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 ClinicalTrials.gov (NCT01794520) Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
3 ClinicalTrials.gov (NCT01794507) A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
4 ClinicalTrials.gov (NCT02640833) A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
5 ClinicalTrials.gov (NCT04447716) An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
6 ClinicalTrials.gov (NCT02992522) Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
7 ClinicalTrials.gov (NCT01969682) A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
8 ClinicalTrials.gov (NCT03874052) Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
9 ClinicalTrials.gov (NCT03955783) Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
10 ClinicalTrials.gov (NCT04687761) Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
11 ClinicalTrials.gov (NCT05455294) Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
12 ClinicalTrials.gov (NCT03471260) Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
13 ClinicalTrials.gov (NCT02203773) Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
14 ClinicalTrials.gov (NCT05342584) Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
15 ClinicalTrials.gov (NCT04140487) Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
16 ClinicalTrials.gov (NCT05520567) A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
17 ClinicalTrials.gov (NCT04214860) APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
18 ClinicalTrials.gov (NCT01969669) A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
19 ClinicalTrials.gov (NCT02942290) A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Nave Higher-Risk Myelodysplastic Syndromes (MDS)
20 ClinicalTrials.gov (NCT02670044) A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
21 ClinicalTrials.gov (NCT04874194) Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
22 ClinicalTrials.gov (NCT03867682) Venetoclax and Lintuzumab-Ac225 in AML Patients
23 ClinicalTrials.gov (NCT04512105) Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
24 ClinicalTrials.gov (NCT02287233) A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Nave Participants With Acute Myelogenous Leukemia
25 ClinicalTrials.gov (NCT05506332) Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
26 ClinicalTrials.gov (NCT03379051) Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
27 ClinicalTrials.gov (NCT04543916) Venetoclax and Irinotecan in Relapsed/Refractory SCLC
28 ClinicalTrials.gov (NCT05263284) 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
29 ClinicalTrials.gov (NCT04092179) Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
30 ClinicalTrials.gov (NCT03441555) A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
31 ClinicalTrials.gov (NCT03884972) Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
32 ClinicalTrials.gov (NCT04926285) Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)
33 ClinicalTrials.gov (NCT03886649) Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
34 ClinicalTrials.gov (NCT03625505) A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
35 ClinicalTrials.gov (NCT04274933) A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
36 ClinicalTrials.gov (NCT05054465) A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
37 ClinicalTrials.gov (NCT05618366) Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
38 ClinicalTrials.gov (NCT03844815) Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
39 ClinicalTrials.gov (NCT03751436) Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
40 ClinicalTrials.gov (NCT03735875) Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
41 ClinicalTrials.gov (NCT04572763) Copanlisib Plus Venetoclax in R/R DLBCL
42 ClinicalTrials.gov (NCT03484520) A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
43 ClinicalTrials.gov (NCT06232655) Cladribine Venetoclax in Monocytic AML
44 ClinicalTrials.gov (NCT06014489) A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
45 ClinicalTrials.gov (NCT03567616) A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
46 ClinicalTrials.gov (NCT05433532) Study of AzacitidineVenetoclaxand Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
47 ClinicalTrials.gov (NCT03584009) A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
48 ClinicalTrials.gov (NCT05736978) Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
49 ClinicalTrials.gov (NCT05736965) A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Nave Participants With Acute Myeloid Leukemia
50 ClinicalTrials.gov (NCT04905407) Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML
51 ClinicalTrials.gov (NCT04487106) Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
52 ClinicalTrials.gov (NCT05401097) IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
53 ClinicalTrials.gov (NCT04802590) Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
54 ClinicalTrials.gov (NCT05805098) Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
55 ClinicalTrials.gov (NCT02471391) ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)
56 ClinicalTrials.gov (NCT04285268) Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
57 ClinicalTrials.gov (NCT05168930) Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
58 ClinicalTrials.gov (NCT03534180) Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
59 ClinicalTrials.gov (NCT04990778) Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
60 ClinicalTrials.gov (NCT03836261) Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
61 ClinicalTrials.gov (NCT05057494) A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
62 ClinicalTrials.gov (NCT02755597) A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
63 ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.
64 ClinicalTrials.gov (NCT03462719) A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
65 ClinicalTrials.gov (NCT02950051) Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation